2. Gene
  3. Dll4 - delta like canonical Notch ligand 4 Gene

Dll4 - delta like canonical Notch ligand 4 Gene

  • Gene
  • Protein
  • Agent
  • Ortholog
Rattus norvegicus
Gene ID: 311332 | Gene type: protein coding

About Dll4

Summary

Predicted to enable Notch binding activity. Predicted to be involved in several processes, including cellular response to growth factor stimulus; circulatory system development; and regulation of Notch signaling pathway. Predicted to act upstream of or within angiogenesis; negative regulation of blood vessel endothelial cell migration; and regulation of neurogenesis. Predicted to be integral component of membrane. Predicted to be active in plasma membrane. Human ortholog(s) of this gene implicated in Adams-Oliver syndrome. Orthologous to human DLL4 (delta like canonical Notch ligand 4). [provided by Alliance of Genome Resources, Apr 2022]

Dll4 Products(1)

mRNA Protein Name
NM_001107760.1 NP_001101230.1 delta-like protein 4 precursor
Gene Ontology
  • Biological Process
Biological Process GO Annotation Evidence Reference Source
involved in cellular response to cholesterol IEP
IEP: Inferred from expression pattern
28472949 RGD
involved in cellular response to hypoxia IEP
IEP: Inferred from expression pattern
30653356 RGD
involved in chondrocyte differentiation IEP
IEP: Inferred from expression pattern
26872979 RGD
involved in luteolysis IEP
IEP: Inferred from expression pattern
21209419 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

delta-like protein 4

delta-like 4

delta4

drosophila Delta homolog 4

Related Agents

Clinical Phase
Inhibitory Antibodies (4)
Cat. No. Product Name Effect
Purity Phase
HY-P99377 Navicixizumab Inhibitor 99.83% Phase 3
HY-P99261 Demcizumab Inhibitor ≥95.0% Phase 2
HY-P99852 Dilpacimab Inhibitor / Phase 2
HY-P99925 Enoticumab Inhibitor 99.64% Phase 1
Pre-clinical Phase
Bioactive Molecules (4)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-122094 Steppogenin Inhibitor 99.49% Unkown
HY-RS03810 DLL4 Human Pre-designed siRNA Set A Pre-designed Sets / Unkown
HY-RS16878 Dll4 Mouse Pre-designed siRNA Set A Pre-designed Sets / Unkown
HY-RS23320 Dll4 Rat Pre-designed siRNA Set A Pre-designed Sets / Unkown
Inhibitory Antibodies (2)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P991033 Tovecimig / Unkown
HY-P991423 MEDI0639 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Dll4 NCBI NCBI:54567
Mus musculus Dll4 NCBI NCBI:54485
Macaca mulatta Dll4 NCBI NCBI:704898